Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer entities : Takeda pharmaceutical company limited save search
Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -0.0%
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: 0.26%
H: 1.36%
C: 1.36%
AZNCF | $135.305 -4.19% 1.1K
|
Health Technology
|
| O: -0.85%
H: 1.12%
C: 0.43%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
UCBJY | $63.31 -4.38% 9.4K
|
Manufacturing
|
| O: 1.46%
H: 0.44%
C: 0.44%
ALPMY | News | $9.34 -1.11% 690K
|
Manufacturing
|
| O: -0.27%
H: 0.0%
C: -1.17%
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: -0.2%
H: 0.14%
C: -0.48%
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.29%
GSK | $39.6 -0.88% 0.0% 2.8M
|
Health Technology
|
| O: -0.69%
H: 1.42%
C: 1.22%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: -0.65%
H: 1.63%
C: 1.48%
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
|
| O: -0.88%
H: 1.46%
C: 1.13%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: 0.0%
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: -2.81%
H: 2.08%
C: 1.38%
AMGN | $264.07 -0.59% -0.59% 2.2M
|
Health Technology
|
| O: -0.35%
H: 1.15%
C: 0.96%
lung reach cancer cell diagnostics therapy market
Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published: 2024-02-06 (Crawled : 00:00) - prnewswire.com
ALPMF | News | $9.594 43.47% 2.2K
|
Health Technology
|
| O: -1.53%
H: 0.0%
C: 0.0%
AZNCF | $135.305 -4.19% 1.1K
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
UCBJY | $63.31 -4.38% 9.4K
|
Manufacturing
|
| O: 1.71%
H: 1.28%
C: 0.94%
ALPMY | News | $9.34 -1.11% 690K
|
Manufacturing
|
| O: 0.28%
H: 0.18%
C: 0.0%
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: 0.07%
H: 0.42%
C: 0.07%
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
|
| O: 0.09%
H: 0.39%
C: -0.36%
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: 1.47%
H: 0.0%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.76%
H: 4.31%
C: 2.11%
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: -0.14%
H: 0.35%
C: -1.12%
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
|
| O: 1.48%
H: 0.0%
C: 0.0%
VRTX | $393.1 -0.27% -0.27% 880K
|
Health Technology
|
| O: 0.15%
H: 2.4%
C: 0.56%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
JAZZ | News | $107.15 -1.61% -1.63% 590K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: -1.4%
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: -0.4%
H: 0.19%
C: -0.33%
AMGN | $264.07 -0.59% -0.59% 2.2M
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: -6.22%
report cancer blood growth market
United States Endometrial Cancer Research Report 2023
Published: 2024-02-02 (Crawled : 10:00) - prnewswire.com
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: 0.21%
H: 0.49%
C: -0.9%
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
|
| O: -0.5%
H: 0.26%
C: -1.03%
report cancer research
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: -0.27%
H: 0.07%
C: -0.07%
EXEL | $22.875 0.24% 0.24% 2.8M
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: -0.23%
ntact-02 asco cancer trial results
FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)
Published: 2023-11-21 (Crawled : 18:00) - biospace.com/
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: 0.07%
H: 0.57%
C: 0.0%
cancer treatment
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | News | $9.34 -1.11% 690K
|
Manufacturing
|
| O: -1.46%
H: 3.67%
C: 3.26%
ZYME | $8.86 -0.78% -0.79% 370K
|
Health Technology
|
| O: 1.14%
H: 0.42%
C: -0.7%
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
ADCT | $4.96 11.71% 1.41% 1.2M
|
Health Technology
|
| O: -0.16%
H: 6.42%
C: 4.49%
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
STRO M | $3.78 -4.06% -4.23% 720K
|
Health Technology
|
| O: 0.39%
H: 3.86%
C: 3.86%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
GILD | $66.94 -0.55% -0.55% 5.3M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
EXEL | $22.875 0.24% 0.24% 2.8M
|
Health Technology
|
| O: -2.62%
H: 1.17%
C: -1.66%
drug antibody breast cancer treatment global market
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-08-21 (Crawled : 05:00) - globenewswire.com
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: -0.4%
H: 0.6%
C: 0.47%
EXEL | $22.875 0.24% 0.24% 2.8M
|
Health Technology
|
| O: 0.28%
H: 1.32%
C: 0.99%
ntact-02 positive cancer trial results
Global Cancer Therapies Strategic Business Report 2023: Industry Focuses on New Approaches to Treat Cancer
Published: 2023-06-27 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: -0.95%
H: 0.19%
C: -0.32%
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 0.19%
H: 0.11%
C: -1.46%
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
|
| O: -0.01%
H: 0.16%
C: -0.32%
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: 0.03%
H: 0.12%
C: -0.24%
GSK | $39.6 -0.88% 0.0% 2.8M
|
Health Technology
|
| O: -0.91%
H: 0.56%
C: -0.5%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 2.15%
H: 1.18%
C: 0.43%
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.0%
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: -0.21%
H: 0.42%
C: 0.13%
report business cancer treat global
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
Published: 2023-06-15 (Crawled : 14:20) - globenewswire.com
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: -0.31%
H: 0.78%
C: 0.69%
HCM | $16.45 -1.38% -1.4% 290K
|
Health Technology
|
| O: 2.46%
H: 9.6%
C: 5.6%
authorization cancer application
Global Peptide Therapeutics Market Report 2023: Increasing Prevalence of Cancer and Metabolic Disorders Drives Growth
Published: 2023-06-08 (Crawled : 02:00) - prnewswire.com
AZNCF | $135.305 -4.19% 1.1K
|
Health Technology
|
| O: 0.07%
H: 0.0%
C: -1.7%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: -0.62%
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: -0.62%
H: 0.88%
C: 0.81%
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
|
| O: 1.26%
H: 1.08%
C: 0.91%
GSK | $39.6 -0.88% 0.0% 2.8M
|
Health Technology
|
| O: 0.41%
H: 0.68%
C: 0.64%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.11%
H: 2.66%
C: 2.24%
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: 0.28%
H: 0.42%
C: -0.05%
BNTX | $86.42 0.09% 0.09% 1.2M
|
Health Technology
|
| O: 0.39%
H: 0.15%
C: -0.79%
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: -0.23%
H: 1.83%
C: 1.52%
AMGN | $264.07 -0.59% -0.59% 2.2M
|
Health Technology
|
| O: 0.0%
H: 0.28%
C: -0.23%
metabolic report cancer global therapeutics growth market
Targeted Therapy Global Market Report 2023: Increasing Prevalence of Cancer Drives Growth
Published: 2023-05-15 (Crawled : 17:00) - prnewswire.com
GNMSF | $285.11 3.83% 420
|
Health Technology
|
| O: 0.24%
H: 0.66%
C: 0.66%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: 0.61%
H: 0.3%
C: 0.24%
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
|
| O: 0.2%
H: 0.13%
C: -0.22%
GSK | $39.6 -0.88% 0.0% 2.8M
|
Health Technology
|
| O: 0.27%
H: 0.6%
C: 0.41%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
GMAB | $28.51 -3.13% -3.23% 360K
|
Health Technology
|
| O: 0.38%
H: 0.91%
C: 0.69%
AMGN | $264.07 -0.59% -0.59% 2.2M
|
Health Technology
|
| O: 0.14%
H: 0.28%
C: 0.11%
report cancer global therapy growth market
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
Published: 2023-03-31 (Crawled : 01:00) - globenewswire.com
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: 0.0%
H: 0.92%
C: 0.8%
HCM | $16.45 -1.38% -1.4% 290K
|
Health Technology
|
| O: -1.19%
H: 2.04%
C: -1.66%
fda cancer treatment submission
Endometriosis Drugs Global Market Report 2023: Emerging Treatments for Endometriosis & Endometrial Cancer Present Opportunities
Published: 2023-03-11 (Crawled : 04:20) - prnewswire.com
ALPMF | News | $9.594 43.47% 2.2K
|
Health Technology
| Email alert
Add to watchlist
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | $135.305 -4.19% 1.1K
|
Health Technology
| Email alert
Add to watchlist
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
| Email alert
Add to watchlist
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
| Email alert
Add to watchlist
ALPMY | News | $9.34 -1.11% 690K
|
Manufacturing
| Email alert
Add to watchlist
global report cancer market
Global Head And Neck Cancer Therapeutics Market Report 2022: Sector to Reach $2.5 Billion by 2028 at a 12.3% CAGR
Published: 2023-01-12 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.13%
H: 0.76%
C: 0.76%
AZNCF | $135.305 -4.19% 1.1K
|
Health Technology
|
| O: 2.77%
H: 0.63%
C: 0.63%
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: 0.13%
H: 2.35%
C: 2.16%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.13%
H: 1.04%
C: 0.57%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: 1.27%
H: 0.78%
C: 0.15%
global report therapeutics cancer market
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
Published: 2022-12-08 (Crawled : 23:00) - biospace.com/
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: -0.07%
H: 1.09%
C: 1.09%
ntact-01 lung immunotherapy trial update cancer
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
Published: 2022-12-08 (Crawled : 22:00) - biospace.com/
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: -0.07%
H: 1.09%
C: 1.09%
EXEL | $22.875 0.24% 0.24% 2.8M
|
Health Technology
|
| O: 0.0%
H: 1.59%
C: 1.04%
ntact-01 lung immunotherapy trial update cancer
Global Cancer Therapies Market Report 2022: Market to Reach $209.2 Billion by 2026 - Industry Focuses on New Approaches to Treat Cancer
Published: 2022-08-03 (Crawled : 19:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.22%
H: 1.8%
C: 1.8%
AZNCF | $135.305 -4.19% 1.1K
|
Health Technology
|
| O: 2.52%
H: 0.0%
C: -0.19%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -2.88%
H: 0.0%
C: -0.21%
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: -0.29%
H: 0.72%
C: 0.58%
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: 0.08%
H: 0.29%
C: -0.08%
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
|
| O: 0.2%
H: 0.44%
C: 0.24%
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: 1.4%
H: 0.0%
C: 0.0%
GSK | $39.6 -0.88% 0.0% 2.8M
|
Health Technology
|
| O: 0.27%
H: 0.1%
C: -0.81%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -1.16%
H: 0.02%
C: -1.42%
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: -0.27%
H: 0.22%
C: -0.92%
AZN | $68.53 0.39% 0.39% 3.7M
|
Health Technology
|
| O: 1.13%
H: 0.35%
C: 0.35%
global report cancer market
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
Published: 2022-07-11 (Crawled : 13:00) - biospace.com/
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: 0.91%
H: 0.35%
C: -0.21%
EXEL | $22.875 0.24% 0.24% 2.8M
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: -5.67%
osmic-313 kidney trial cancer phase 3 nivolumab
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
Published: 2022-05-26 (Crawled : 00:00) - biospace.com/
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
EXEL | $22.875 0.24% 0.24% 2.8M
|
Health Technology
|
| O: 0.11%
H: 0.0%
C: 0.0%
osmic-021 trial asco results cancer urothelial carcinoma
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-05-03 (Crawled : 18:00) - biospace.com/
TAK | $13.15 -0.61% 0.0% 1.6M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
EXEL | $22.875 0.24% 0.24% 2.8M
|
Health Technology
|
| O: 0.09%
H: 1.54%
C: -0.44%
cabometyx approval cancer
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.